Partnerships PDF Print E-mail

We are actively seeking regional strategic partners for our preclinical and clinical programs that either are not currently in development or for territories where we do not plan to pursue development.

Agreements to date include:

Merck KgaA
Tumor Necrosis Therapy for delivery of cytokines.

Affitech AS
Generation of fully human antibodies against targets identified by Peregrine. Licensed exclusive worldwide rights to develop and commercialize products under Peregrine's selective anti-VEGF intellectual property portfolio including the fully human antibody r84.

Read more about this partnership...

Stason Pharmaceuticals
Tumor Necrosis Therapy technologies in certain Asia-Pacific Economic Cooperation (APEC) countries.

Read more about this partnership...